Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment

To compare 2‐year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS)